Public healthCanada

Elective egg freezing cycles see sharp increase among Canadians

Egg-freezing retrievals in Canada rose from 217 cycles in 2013 to 2,663 in 2025, with over 22,000 eggs banked last year, up from 775, per the Canadian Fertility and Andrology Society. Doctors cite high living costs, career ambitions, later parenthood and a lack of a partner. A cycle typically costs $11,000-$16,000 with medication and a year of storage, and public funding does not cover elective freezing. Freezing 20-25 eggs in the early 30s gives about a 75% chance of a baby, but success is never guaranteed - and only about 11% of people who froze eggs have gone back to thaw them.

Elective fertility preservation is surging while staying out of reach for many: a cycle costs $11,000-$16,000 with no public funding. Anyone considering it should know the costs, the odds, and that a fertility-clinic consultation is the recommended first step.

Ask about this brief

Answers are written by AI from this brief and can be wrong. Check the original source before you act.

2 free questions a day without an account. Members ask as often as they like, free.

Not medical, legal or immigration advice. Questions are kept anonymously to improve our briefs.

Read the original

News source: Elective egg freezing cycles see sharp increase among Canadians (opens in a new tab) — CBC News

Report a problem

Due in 20 daysPublic healthCanada

Accel Pharma reports upcoming two-week shortage of ondansetron 8 mg tablets

Accel Pharma reports its ondansetron orally-disintegrating tablet 8 mg (ACCEL-ONDANSETRON ODT, DIN 02535327) faces an anticipated shortage from Nov 1 to Nov 15, 2026, caused by a shortage of an active ingredient.

Ondansetron is a widely used anti-nausea drug — pharmacies should check stock and alternatives before the anticipated shortage starts Nov 1.

Due in 20 daysPublic healthCanada

Accel Pharma reports upcoming two-week shortage of ondansetron 4 mg tablets

Accel Pharma reports its ondansetron orally-disintegrating tablet 4 mg (ACCEL-ONDANSETRON ODT, DIN 02535319) faces an anticipated shortage from Nov 1 to Nov 15, 2026, caused by a shortage of an active ingredient.

Ondansetron is a widely used anti-nausea drug — pharmacies should check stock and alternatives before the anticipated shortage starts Nov 1.

Due in 39 daysPublic healthCanada

Sandoz rabeprazole 20 mg supply disruption expected until early December

Sandoz Canada reports its rabeprazole sodium 20 mg enteric-coated tablet (DIN 02314185) faces an anticipated shortage from Oct 26 to Dec 4, 2026, after a disruption in the manufacture of the drug.

Rabeprazole is a commonly prescribed stomach-acid drug — prescribers and pharmacies should plan alternatives while the shortage is expected.

Due in 18 daysPublic healthCanada

Sandoz dexamethasone injection supply faces temporary shortage through mid-November

Sandoz Canada reports its dexamethasone sodium phosphate injection 10 mg/mL (DIN 00874582), for intravenous, intramuscular or intrasynovial use, faces an anticipated shortage from Oct 26 to Nov 13, 2026, driven by increased demand.

Dexamethasone injection is a staple steroid in hospitals and clinics — care teams should check stock before the anticipated shortage bites.